Sara Tolaney: Such an important question addressed in the Alliance A011502 study

Sara Tolaney shared a post by Erman Akkus, Medical Oncology Fellow at Ankara University, on X/Twitter:

“Such an important question addressed in the Alliance A011502 study looking at adjuvant aspirin in breast cancer found no benefit.

Wonderful work by Wendy Chen and the Alliance team!”

Quoting Erman Akkus’s post:

“Adjuvant Aspirin in Breast Cancer

The Alliance A011502 randomized phase 3 trial.

Negative study, lack of benefit for invasive DFS and OS.

3020 participants
high-risk nonmetastatic breast cancer
Aspirin vs placebo
By median follow-up of 33.8 months,
invasive DFS, HR:1.27 (95% CI, 0.99-1.63; P = .06)
OS, HR: 1.19 (95% CI, 0.82-1.72).”

Visit the article website.
Source: Sara Tolaney/X and Erman Akkus/X

Sara Tolaney is the Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute. She also serves as Associate Director of the Susan F. Smith Center for Women’s Cancers and is a Senior Physician at Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School. Her research focuses on the development of novel therapies in the treatment of breast cancer and developing more effective and less toxic treatment approaches. Her work has demonstrated that a relatively low risk regimen is beneficial in women with early stage node-negative HER2-positive cancers, and this works has been incorporated into national and international guidelines. She has developed several follow-up studies looking at novel approaches to early stage HER2-positive disease and has also played a significant role in development of cdk 4/6 inhibitors, antibody drug conjugates, and immunotherapy in breast cancer. She is the author of over 150 peer-reviewed publications in leading scientific journals. She is the recipient of the Lee M Nadler “Extra Mile” Award, and the Innovation Award for Clinical Faculty.